Aurinia Pharmaceuticals Inc
SWB:IKAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurinia Pharmaceuticals Inc
SWB:IKAP
|
CA |
|
Mastercraft Boat Holdings Inc
NASDAQ:MCFT
|
US |
|
W
|
Williams Companies Inc
XBER:WMB
|
US |
|
T
|
TCS Group Holding PLC
XMUN:13T1
|
CY |
Wall St Price Targets
IKAP Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for IKAP is 15.36 EUR with a low forecast of 13.42 EUR and a high forecast of 19.53 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IKAP's stock price target?
Price Target
15.36
EUR
According to Wall Street analysts, the average 1-year price target for IKAP is 15.36 EUR with a low forecast of 13.42 EUR and a high forecast of 19.53 EUR.
What is the Revenue forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 16%.
What is the Gross Profit forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
22%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 33%. The projected CAGR for the next 3 years is 22%.
What is the Operating Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Operating Income over the next 8 years is 24%.
What is the Pre-Tax Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
33%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 33%.
What is the Net Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
6%
The compound annual growth rate for Net Income over the next 8 years is 6%.
